Eli Lilly's Weight-Loss Drugs Fuel Beat-And-Raise Quarter Eli Lilly stock is surging after the pharma giant beat Q2 estimates and lifted its full-year outlook. Here's what you need to know. Kiplinger · Aug 8, 2024
3 Biotech Stocks With Anticipated Strong Earnings Reports With highly effective drugs and treatment options, chronic disease prevalence, and adoption of technology, the biotech market is thriving. Hence, fundamentally solid biotech stocks Illumina (ILMN), Amgen (AMGN), and Entrada Therapeutics (TRDA) could be ideal with anticipated strong earnings reports. Read more. StockNews.com · Aug 5, 2024
Drugstores tinker with new looks as their usual way of doing business faces challenges America’s drugstores are testing smaller locations and more ways to offer care as more store closings loom The Independent UK · Aug 4, 2024
GSK’s health is improving. Shame about the legal heartburn Emma Walmsley’s overhaul seems to be delivering the goods even if US worries have left the share price becalmed The Guardian - UK · Jul 31, 2024
Pfizer Stock Slips After Beat-And-Raise Quarter: What to Know Pfizer reported a notable year-over-year decline in Q2 earnings, but the results still beat expectations. Here's what investors should know. Kiplinger · Jul 30, 2024
Reckitt Benckiser’s shares slump after Abbott baby formula ruling over bowel disease link British group says claims products cause serious bowel condition NEC are ‘not supported by science’ The Guardian - UK · Jul 29, 2024
'Grinding halt': shortage could cause hospital chaos Australia's health system could come to a "grinding halt" within days if a shortage of intravenous fluid isn't addressed, a leading doctor has warned. AAP · Jul 26, 2024
Bosses Resign At Japan Health Supplement Firm Probing Deaths The chairman and president of a major Japanese dietary supplement maker announced their resignation on Tuesday, as the company probes dozens of deaths potentially linked to products meant to lower cholesterol. International Business Times · Jul 23, 2024
Dear Pharmac – do things differently: what David Seymour’s expectations could mean for the drug-buying agency Associate Health Minister David Seymour’s recent letter of expectations to drug buying agency Pharmac could fundamentally change the way the organisation makes decisions. Some of these changes could also make Pharmac’s job harder and its decisions more unpopular. The Conversation · Jul 22, 2024
Ozempic knockoffs flood US market thanks to ‘blind spot’ in FDA rules Pharmacy alliance president counters that ‘it’s an intentional policy’ so patients don’t go without medication The Guardian - US · Jul 22, 2024
UN Urges Gilead To 'Make History' With Game-changing HIV Drug Gilead could bring the AIDS pandemic towards an end if the US pharmaceutical giant opens up access to its game-changing new HIV drug, the head of UNAIDS told AFP. Winnie Byanyima urged Gilead to "make history" by allowing generic manufacturing of Lenacapavir, a twice-yearly injectable antiretroviral medication used to treat… International Business Times · Jul 22, 2024
3 Healthcare Stocks With High Profit Margins With an aging population, increasing drug demand, and the development of advanced technologies, the healthcare industry is booming. Thus, it could be wise to invest in fundamentally sound healthcare stocks, Veeva Systems (VEEV), Align Technology (ALGN), and Medpace Holdings (MEDP), which have high-profit margins. Read on. StockNews.com · Jul 18, 2024
3 Pharmaceutical Stocks With Strong Pipelines The pharmaceutical industry is flourishing due to increasing medical demands and rising healthcare spending worldwide. Hence, pharma stocks Eli Lilly (LLY), Johnson & Johnson (JNJ), and Merck & Co. (MRK), with strong pipelines, might be worth buying. Read more…. StockNews.com · Jul 18, 2024
Shanghai Composite Index Ended Nearly Flat on Friday Shenzhen Component Index closed down 0.18% Caixin Global · Jul 12, 2024
The Independent UK · Jul 9, 2024 The threat of litigation looms as Purdue Pharma returns to settlement talks OxyContin maker Purdue Pharma, the family that owns it and lawyers for thousands of parties with claims against it are getting ready to work on a new settlement after the U.S. Supreme Court rejected the last one
The Independent UK · Jul 9, 2024 South Africa drops probe of J&J after it agrees to lower price of TB drug and withdraws patent Medical advocacy groups welcomed Johnson & Johnson’s decision not to enforce its patent on a critical tuberculosis medication, allowing its production at much lower prices, after South African authorities opened an investigation into the conglomerate
Evening Standard · Jul 9, 2024 London biotech secures £90 million backing Myricx Bio’s £90 million Series A fundraising will initially focus on developing its work treating solid tumours, such as breast and gastric cancers, but potentially can apply across all cancers
StockNews.com · Jul 2, 2024 3 Mid-Cap Stocks Analysts Believe Will Soar 50% or More The blend of growth potential and stability in mid-cap pharma stocks is driven by rising demand for innovative therapies, strong economic conditions, and technological advancements that boost the sector's growth trajectory. Therefore, considering strong mid-cap stocks like Amphastar Pharmaceuticals (AMPH), Catalyst Pharmaceuticals (CPRX), and ACADIA Pharmaceuticals (ACAD), expected to soar…
International Business Times · Jun 28, 2024 US Supreme Court Rejects Opioid Settlement That Shields Sackler Family The US Supreme Court on Thursday rejected Purdue Pharma's $6 billion opioids settlement immunizing the Sackler family, which controlled the drugmaker, from future litigation.
The Independent UK · Jun 27, 2024 Walgreens will close a ‘significant’ number of failing stores across US There are 8,500 Walgreens stores across the country, and around a quarter are failing
The Conversation · Jun 27, 2024 Supreme Court rejects settlement with OxyContin maker Purdue Pharma over legal protections for the Sackler family that owned the company The Supreme Court ruled 5-4 against an estimated US$6 billion Purdue Pharma bankruptcy plan on June 27, 2024, that would have shielded the Sackler family – which owned and controlled the company – from legal liability.
France 24 · Jun 27, 2024 US Supreme Court rejects $6 billion OxyContin settlement shielding Sackler family The US Supreme Court on Thursday rejected OxyContin maker Purdue Pharma's $6 billion settlement that would have shielded the Sackler family, who owned the company and earned tens of billions as it flooded the country with the highly addictive drug, from future civil lawsuits over the role they played in…
The Independent UK · Jun 27, 2024 The legal odyssey for OxyContin maker Purdue Pharma and its owners is complex. Here's what to know The Supreme Court has rejected a settlement for OxyContin maker Purdue Pharma and members of the Sackler family who own the company
The Independent UK · Jun 27, 2024 Supreme Court shreds nationwide $6 billion opioid settlement plan in ruling against Sackler family The Supreme Court said the Sackler family cannot use a Chapter 11 reorganization plan to protect themselves from civil liability
The Guardian - US · Jun 27, 2024 US supreme court blocks Purdue Pharma’s bankruptcy settlement that would shield Sacklers from lawsuits Controversial deal would have protected billionaire family owners from further liability over US opioid epidemic